 | Up a level |
Fasching, Peter A; Hack, Carolin C; Nabieva, Naiba; Maass, Nicolai; Aktas, Bahriye; Kümmel, Sherko; Thomssen, Christoph; Wolf, Christopher; Kolberg, Hans-Christian; Brucker, Cosima; Janni, Wolfgang; Dall, Peter; Schneeweiss, Andreas; Marme, Frederik; Sütterlin, Marc W; Ruebner, Matthias; Theuser, Anna-Katharin; Kellner, Sara; Hofmann, Nadine M; Böhm, Sybille; ... (2024). Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole. European journal of cancer, 209, p. 114239. Elsevier 10.1016/j.ejca.2024.114239
Hack, Carolin C; Maass, Nicolai; Aktas, Bahriye; Kümmel, Sherko; Thomssen, Christoph; Wolf, Christopher; Kolberg, Hans-Christian; Brucker, Cosima; Janni, Wolfgang; Dall, Peter; Schneeweiss, Andreas; Marme, Frederik; Ruebner, Matthias; Theuser, Anna-Katharin; Hofmann, Nadine M; Böhm, Sybille; Almstedt, Katrin; Kellner, Sara; Gass, Paul; Sütterlin, Marc W; ... (2024). Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study. Geburtshilfe und Frauenheilkunde, 84(2), pp. 185-195. Thieme 10.1055/a-2238-3153
Hack, Carolin C; Maass, Nicolai; Aktas, Bahriye; Kümmel, Sherko; Thomssen, Christoph; Wolf, Christopher; Kolberg, Hans-Christian; Brucker, Cosima; Janni, Wolfgang; Dall, Peter; Schneeweiss, Andreas; Marme, Frederik; Ruebner, Matthias; Theuser, Anna-Katharin; Hofmann, Nadine M; Böhm, Sybille; Almstedt, Katrin; Kellner, Sara; Nabieva, Naiba; Gass, Paul; ... (2024). Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study. Geburtshilfe und Frauenheilkunde, 84(2) Thieme 10.1055/a-2314-3693
Goldhirsch, Aron; Gelber, Richard D.; Piccart-Gebhart, Martine J.; de Azambuja, Evandro; Procter, Marion; Suter, Thomas; Jackisch, Christian; Cameron, David; Weber, Harald A.; Heinzmann, Dominik; Dal Lago, Lissandra; McFadden, Eleanor; Dowsett, Mitch; Untch, Michael; Gianni, Luca; Bell, Richard; Köhne, Claus-Henning; Vindevoghel, Anita; Andersson, Michael; Brunt, A Murray; ... (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, 382(9897), pp. 1021-1028. Elsevier 10.1016/S0140-6736(13)61094-6
Cameron, David; Brown, Julia; Dent, Rebecca; Jackisch, Christian; Mackey, John; Pivot, Xavier; Steger, Guenther G.; Suter, Thomas M.; Toi, Masakazu; Parmar, Mahesh; Laeufle, Rita; Im, Young-Hyuck; Romieu, Gilles; Harvey, Vernon; Lipatov, Oleg; Pienkowski, Tadeusz; Cottu, Paul; Chan, Arlene; Im, Seock-Ah; Hall, Peter S.; ... (2013). Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. The lancet oncology, 14(10), pp. 933-942. Elsevier 10.1016/S1470-2045(13)70335-8
von Minckwitz, Gunter; Untch, Michael; Nüesch, Eveline; Loibl, Sibylle; Kaufmann, Manfred; Kümmel, Sherko; Fasching, Peter A; Eiermann, Wolfgang; Blohmer, Jens-Uwe; Costa, Serban Dan; Mehta, Keyur; Hilfrich, Jörn; Jackisch, Christian; Gerber, Bernd; du Bois, Andreas; Huober, Jens; Hanusch, Claus; Konecny, Gottfried; Fett, Werner; Stickeler, Elmar; ... (2011). Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast cancer research and treatment, 125(1), pp. 145-156. Dordrecht: Springer 10.1007/s10549-010-1228-x
